The Pharmaceutical Cannabis Report: 3rd Edition

This report gives a clear and detailed account of all activity involving cannabis and cannabinoids in the landscape of pharmaceutical medicine, at a global level. The main topics covered include an analysis of the relevant landscape in clinical trials, patents and innovation. As well as this, a market-sizing forecast for the global pharmaceutical cannabis industry for the period 2023–2027 is presented, with accompanying commentary, and a short analysis of the recent M&A activity and research funding activity relevant to the sector is included. Discussion of the topics covered is informed and supported by extensive data produced during research for the report. Throughout the main sections, this data is visualised in order to provide evidence and clarification to analysis. Whenever possible, context is provided to explain the factors that have brought about the current circumstances in the relevant sphere of activity, and what constraints face those operating within it. Recent developments and trends are highlighted in order to draw attention to the most significant dynamics in each area.

• · Executive Summary
• · Introduction
• · Overview
• · Drug Development - Costs & Relevant Factors
• · Main Players
• · Geographies
• · Clinical Trials
• · Expert Interviews
• · Patents
• · Innovation
• · M&A Activity
• · Market Sizing
• · Conclusion

• · Global sales within the pharmaceutical cannabis industry are estimated to reach approximately US$1.11 billion in 2023, with projected growth to US$1.37 billion by 2027.
• · Epidiolex (Epidyolex in Europe) is the dominant player in the market, with an estimated market share of around 76% projected for 2023.
• · In the pharmaceutical cannabis industry, the only drug to generate significant sales (of approximately €160 million annually) apart from Epidiolex and Sativex is dronabinol.
• · There is growing interest in research around non-cannabinoid compounds targeting the endocannabinoid system. Jazz Pharmaceuticals dominated the patent landscape for the medical application of cannabinoids, and has a patent portfolio which dwarfs that of any other company involved in patenting activity around the medical application of cannabinoids.
• · CBD and THC are still seeing the majority of patent activity versus other cannabinoids, as they have historically. A large amount of activity is also focused on cannabinoids and compounds that are closely related to these cannabinoids, for example CBDV, THCV, CBDA, and relevant prodrugs and analogues.
• · There is a wide variation in the costs associated with each stage of the clinical trials process, but even at the lowest end, bringing a medicine to the market is going to cost US$20 million or more.
• · Pharmaceutical cannabis sales are concentrated in two regions globally – North America and Europe. Within these regions, sales are not evenly distributed but are concentrated in key markets.